A new CAR T-cell therapy, durcabtagene autoleucel, showed promising results in treating relapsed/refractory multiple myeloma ...

In an interview with Targeted Oncology, Chunhui Han, PhD, discussed the use of Ga 68 PSMA-11 for the imaging of metastatic ...

TH17 cells may be a potential biomarker to predict the risk of immune-related adverse events in patients with metastatic ...

Daratumumab plus VRd is a more effective frontline treatment option for patients who cannot undergo immediate transplant, ...

The FDA granted traditional approval to selpercatinib for the treatment of advanced or metastatic RET-mutated medullary ...

Missak Haigentz, MD, highlights some of the significant unmet needs for patients with small cell lung cancer.

Noah M. Merin, MD, PhD, assistant professor at Cedars-Sinai Medicine and medical director of the Hematology and Cellular ...

CML is a complex disease and according to Mauro, decision-making often depends on the stage at diagnosis. He explains that it is crucial to carefully assess both the disease and the patient's overall ...

Olomorasib with pembrolizumab in the first-line showed a 77% overall response rate in patients with KRAS G12C–mutated ...

Binod Dhakal, MD, MS, discusses some of the challenges often seen in the myeloma space, particularly those with lenalidomide-refractory multiple myeloma.

A new drug combination, talquetamab and teclistamab, shows promising results in treating patients with heavily pretreated ...

Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the phase 3 CEPHEUS trial of daratumumab with bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma.